These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16792435)

  • 1. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system.
    Dunn JD; Cannon E; Mitchell MP; Curtiss FR
    J Manag Care Pharm; 2006 May; 12(4):294-302. PubMed ID: 16792435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
    Klepser DG; Huether JR; Handke LJ; Williams CE
    J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
    Harris BN; West DS; Johnson J; Hong SH; Stowe CD
    J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan.
    Liu YM; Ou HT; Yang YK
    J Ment Health Policy Econ; 2014 Dec; 17(4):163-72. PubMed ID: 25599280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
    J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic implications of preference toward reference- versus generic-brand antidepressants in primary care.
    Gultekin O; Aydin V; Bayram D; Atac O; Akici A
    Prim Health Care Res Dev; 2024 Sep; 25():e40. PubMed ID: 39301599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
    Mabasa VH; Ma J
    J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.
    Spence MM; Hui R; Chan J
    J Manag Care Pharm; 2006 Jun; 12(5):377-82. PubMed ID: 16792444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a physician office generic drug sampling system on generic dispensing ratios and drug costs in a large managed care organization.
    Scott AB; Culley EJ; O'Donnell J
    J Manag Care Pharm; 2007 Jun; 13(5):412-9. PubMed ID: 17605512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan.
    West DS; Johnson JT; Hong SH
    J Manag Care Pharm; 2006; 12(1):25-32. PubMed ID: 16420105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of antidepressant prescribing concentration to treatment duration and cost.
    Hodgkin D; Merrick EL; Hiatt D
    J Ment Health Policy Econ; 2012 Mar; 15(1):3-11. PubMed ID: 22611088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.